NCT07659028Not yet recruiting
Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.
A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver/intestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network "BioTransform," two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2. Bilberry /blueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 9 Jun 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Jul 2029
- Lead sponsor
- National and Kapodistrian University of Athens
- Diseases
- Obesity
- NCT number
- NCT07659028
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 1 Jul 2026 to the primary completion date, 1 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Chronic gastrointestinal, inflammatory or metabolic diseases
- Acute infection during the past month
Other
- No signed informed consent
- Supplementation or probiotic usage in the past 8 weeks
- Alcohol misuse
- Pregnancy or breastfeeding
Who the study is looking for
- 30-50 years old,
- BMI\> 25 kg/m2
- prediabetic stage
- hsCRP\> 2mg/ L
- HbA1c 5,7-6,4%
- Impaired fasting glucose (IFG)
- Caucasian
Age in the registry: 30 years to 50 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laiko Hospital Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.